An immune-modulating medication used for a range of conditions.
Reviewed by:
Dr. Steve Malen, PharmD
Dr. Steven Blikstein, PharmD
Strength
How would you like to get this medication?
Choose a strength and quantity to continue.
Cyclosporine is a prescription eye drop used to increase tear production in patients with chronic dry eye disease caused by inflammation. It reduces inflammation in the tear glands, restoring natural tear flow and providing lasting relief from dryness and irritation. Unlike artificial tears, Restasis treats the underlying cause and requires consistent, long-term use for full benefit. It should be used exactly as prescribed, and contact lenses must be removed before application and reinserted 15 minutes later. Continued use is important, as improvement may take 3 to 6 months. Avoid touching the dropper tip to prevent contamination.
Complete a health screening
A short questionnaire about your health history and current symptoms — takes about 2 minutes.
Provider reviews your answers
Provider review within 24 hours.
Prescription fulfilled
If approved, your Rx is sent to Invictus Pharmacy and you're notified by text or email. Free nationwide shipping.
Important safety information
Contraindications for Restasis highlight the importance of patient safety and the identification of conditions that warrant caution or complete avoidance of this medication.
Restasis is contraindicated in individuals with known allergies to cyclosporine or any of the formulation’s inactive ingredients. An allergic reaction to cyclosporine can lead to symptoms ranging from mild local irritation to severe hypersensitivity, which requires intervention.
Individuals should discuss any previous allergic reactions to medications with their healthcare provider before starting Restasis.
Patients with active eye infections or who have experienced recent eye trauma or surgery require careful consideration before starting Restasis. These conditions could exacerbate the risk of further complications or influence the response to treatment.
Additionally, any persistent or worsening symptoms, such as a sensation of a foreign body in the eye or changes in vision, should be promptly evaluated by an eye care professional. Monitoring and assessing these conditions will help ensure safe use of Restasis while maximizing its therapeutic benefits for the patient.
Cyclosporine is an immunosuppressant that reduces inflammation by inhibiting specific immune responses. While widely used for systemic prevention of organ transplant rejection and treatment of autoimmune diseases, cyclosporine can also be formulated for localized ocular use.
When applied topically as an ophthalmic solution, cyclosporine targets ocular surface inflammation—one of the primary causes of chronic dry eye disease.
By calming this inflammatory response, cyclosporine helps restore the eye’s natural ability to produce and maintain healthy tears, protecting the cornea and improving long-term eye comfort.
Note: This medication’s generic and brand-name formulations are used interchangeably throughout this article.
Restasis is a brand-name prescription eye drop that contains cyclosporine as its active ingredient. It is specifically approved for the treatment of chronic dry eye disease associated with ocular inflammation.
Unlike oral or injectable cyclosporine, Restasis works locally in the eyes to increase tear production over time rather than providing immediate lubrication. With consistent use, it improves tear quality, reduces surface damage, and promotes healthier ocular function.
Restasis is intended for long-term management and addresses the underlying inflammatory cause of dry eye rather than just relieving symptoms.
Restasis is primarily used to treat chronic dry eye disease, also known medically as keratoconjunctivitis sicca. It is particularly effective when the disease is caused by underlying inflammation, which disrupts normal tear production.
The primary indication for Restasis is the treatment of chronic dry eye disease in patients whose tear production is presumed to be suppressed due to ocular inflammation. This condition often manifests as persistent dryness, irritation, and discomfort, which can affect one’s quality of life.
By addressing inflammation, Restasis improves tear production and, consequently, eye lubrication and comfort. Its role is vital for individuals who do not respond adequately to over-the-counter treatments such as artificial tears.
Off-label, Restasis may be used for other inflammatory ocular conditions, although its application should be carefully assessed by an eye care professional. Such conditions could include postoperative dry eye or inflammation after certain eye surgeries, in which reducing inflammation may promote healing and symptom relief.
Additionally, Restasis may be considered for moderate-to-severe eye allergy symptoms if inflammation is a contributing factor. However, these uses are less common and should be pursued under professional guidance to ensure safety and efficacy.
Restasis operates by modulating the immune response, specifically to reduce ocular inflammation.
The mechanism of action for Restasis involves cyclosporine inhibiting T-cell activation and proliferation. Suppressing genes responsible for cytokine production alleviates the inflammatory processes that reduce tear secretion.
This immunomodulatory effect increases tear production by addressing a root cause of tear deficiency. The targeted anti-inflammatory action allows the lacrimal glands, which produce tears, to recover and function effectively.
The pharmacokinetics of Restasis include its formulation as an ophthalmic emulsion, which prolongs its presence on the ocular surface and delivers consistent therapeutic effects over time. This emulsion increases residence time and ensures gradual absorption, leading to significant improvement in tear production over several weeks to months.
The therapeutic effects are typically noticeable after 3 to 6 months of regular use, and this time frame may vary with individual response and the severity of dry eye symptoms. The delayed yet sustained release of cyclosporine ensures a gradual reduction in inflammation.
Understanding the proper dosage and administration techniques for Restasis is essential for optimizing its therapeutic outcomes. Correct application ensures that patients receive the maximum benefit from their treatment regimen.
The recommended dosage for Restasis is one drop in each eye, administered twice daily approximately 12 hours apart. This consistent dosing schedule is important to maintain the drug’s anti-inflammatory effect throughout the day.
Restasis should not be administered more frequently than prescribed, as increasing the dose does not enhance efficacy and may increase side effects.
For effective administration, patients should wash their hands thoroughly before administering the medication. Each vial of Restasis is designated for single use and should be discarded immediately after administration to ensure sterility and prevent bacterial contamination.
To apply the drops, patients should gently pull down the lower eyelid to form a pocket, then place one drop in the space between the eyelid and the eye. When used in conjunction with other eye drops, a minimum 15-minute interval should be observed to prevent washout and ensure proper distribution of the medication.
Restasis does not require refrigeration and should be stored at room temperature, away from direct light and moisture.
Although Restasis is generally well-tolerated, it can cause side effects that range in severity. Being informed about these potential risks helps you understand what to expect and when to seek medical advice.
Common side effects of Restasis include a burning sensation upon application, redness, and occasionally blurred vision. Users often inquire, “Will the burn from Restasis eye drops go away?”
Generally, this burning sensation diminishes with continued use as the eyes begin to adjust to the treatment. It is important to persevere with the treatment as the medication’s benefits become more apparent over time. If discomfort persists, seeking advice from an eye care professional is recommended.
Serious adverse effects associated with Restasis are rare. However, they can include eye infections or severe, persistent irritation. Symptoms such as swelling, severe redness, or eye discharge should prompt immediate medical attention, as they may indicate an infection or an adverse reaction.
Monitoring for these symptoms is especially crucial for individuals who have recently undergone eye surgery or have a history of eye infections, as they may be at increased risk of complications.
While Restasis has minimal systemic effects due to its topical application, it is important to be aware of potential interactions to ensure safe usage.
Since Restasis is applied topically, it interacts minimally with systemic medications. However, patients should disclose all medications they are taking to their healthcare provider to rule out any potential for interactions that have not been clearly established.
Due to the minimal systemic absorption, the impact of Restasis on the pharmacokinetics of other drugs, and vice versa, is generally considered negligible.
When using Restasis alongside other eye drops or treatments, the timing of administration is crucial. It is recommended that patients wait at least 15 minutes between different eye medications to minimize the risk of washout and ensure optimum absorption of each product.
This guideline helps prevent interference with the action of Restasis and enhances the overall therapeutic protocol for managing dry eye disease and other ocular conditions.
Administration & Dosage
Restasis is administered as eye drops. Instill one drop into each eye twice daily, about 12 hours apart. Wash your hands thoroughly before use. Tilt your head, pull down the lower eyelid, and squeeze a drop into the pocket formed. Maintain sterility by avoiding contact of the dropper with any surface, including your eyes.
Each Restasis vial is designed for single use to prevent contamination. Use one vial per dose for both eyes and discard it afterward. This practice ensures sterility and effectiveness of the medication. Always follow your healthcare provider’s instructions.
Restasis should typically be used twice daily. Increasing the frequency without a doctor's advice may raise the risk of side effects. It's crucial to adhere to the dosing schedule provided by your healthcare professional to optimize therapeutic outcomes.
Restasis vials should be stored at room temperature, specifically between 15°C and 25°C (59°F to 77°F). Refrigeration is not necessary. However, keep the vials protected from light and heat to preserve their effectiveness until use.
Wait approximately 15 minutes before rinsing your eyes or using any other eye products after applying Restasis. This interval allows adequate absorption of the medication, enhancing its efficacy in relieving dry eye symptoms.
Uses & Mechanism of Action
Restasis is primarily used to manage chronic dry eye syndrome by increasing tear production. This medication is beneficial for patients whose tear production is suppressed due to ocular inflammation, helping alleviate discomfort and restore natural moisture.
Restasis contains cyclosporine, an immunosuppressive agent. It reduces ocular surface inflammation, a cause of suppressed tear production, by targeting the underlying mechanism. Consequently, this treatment increases natural tear production, thereby mitigating symptoms of dry eye syndrome.
Restasis enhances tear production, thereby reducing dry eye symptoms like burning, itching, and redness. Restoring adequate eye moisture alleviates discomfort, thus improving overall eye health and comfort over time with consistent usage.
Restasis is not a steroid. It comprises cyclosporine, an immunosuppressive agent distinct from steroids. While both reduce inflammation, cyclosporine specifically targets eye inflammation to boost tear production without steroid-associated side effects.
The effects of Restasis may take 3 to 6 months to manifest, with gradual increases in tear production and relief from dry eye symptoms. Continuous use is crucial to achieving and maintaining these therapeutic benefits over time.
Side Effects & Safety
Some patients might experience a temporary burning sensation upon Restasis application, initially feeling like symptoms are worse. This is generally transient and subsides as treatment progresses. Consult your eye care provider if symptoms persist.
The burning sensation upon application is a common side effect and often diminishes over time as inflammation decreases. Consistent use usually leads to improvement in this sensation within the first few weeks of treatment.
Restasis is generally safe for its intended use. Nonetheless, some patients might experience side effects. If severe discomfort, vision changes, or allergic reactions occur, contact your healthcare provider promptly for further evaluation and management.
Common Restasis side effects include temporary burning upon application, redness, watery eyes, discharge, eye pain, or a sensation of a foreign body. These effects are usually mild and subside with regular use over time.
To avoid contamination, do not touch the dropper tip to any surface. Restasis should not be used with contact lenses in place. Wait at least 15 minutes after application before reinserting contact lenses for safety and effectiveness.
Interactions & Contraindications
Restasis is the branded version of cyclosporine ophthalmic emulsion, specifically formulated for treating dry eye. The generic name is cyclosporine ophthalmic emulsion, and they are equivalent in terms of effectiveness and safety.
Significant drug interactions have not been widely reported with Restasis. Nevertheless, always inform your healthcare provider about all medications and supplements you use to ensure safe and coordinated care.
Using other ophthalmic medications is generally permissible, though it's advised to wait at least 15 minutes between administering Restasis and other eye drops. This ensures optimal absorption and effectiveness of each medication.
Restasis is preservative-free, supplied in single-use vials. This formulation reduces the risk of ocular irritation associated with preservatives in multi-use bottles. Each vial ensures a sterile, irritation-free application every time.
Like all medications, Restasis has an expiration date. Always verify this date on your package and do not use it past the expiration date to ensure safety and effectiveness. Consult your pharmacist if you have any concerns.
Generic & Alternatives
A generic version of cyclosporine ophthalmic emulsion, equivalent to Restasis, was approved by the FDA. Check with your pharmacy or healthcare provider regarding its availability and any potential cost savings.
Restasis is often a costly medication, and its price can vary by pharmacy and insurance coverage. Patients are encouraged to explore assistance programs or generic options for potential financial relief.
Coverage for Restasis may vary with Medicare plans. Some plans offer partial coverage, which can significantly reduce the cost of the medication. Verify with your specific Medicare plan for detailed coverage information.
Several factors, including production costs and the formulation's specificity in treating chronic dry eye, contribute to Restasis's cost. Until recently, the lack of a generic version also influenced its market price.
Restasis is a prescription medication and is not available over the counter. It requires a prescription from a healthcare provider, who evaluates your condition to determine the appropriate treatment plan.